$LH

LABCORP HOLDINGS INC. (LH) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Contact: Nickolo Russo - Investors Racquel White - Media Investor@labcorp.com Media@labcorp.com Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance • Results from operations for third quarter 2026 versus third quarter 2025: ◦ Re

Labcorp reported 7% Q3 revenue growth, 14.5% adjusted EPS growth, and raised 2026 guidance. The company invested $255.5M in acquisitions and declared a $0.72 quarterly dividend, according to the press release.

Labcorp reported Q3 2026 revenue of $3.81 billion, up 6.9% YoY, and adjusted EPS of $4.78, up 14.5%. The company raised full-year guidance, targeting 5.9% to 6.7% revenue growth and $18.30 to $18.70 adjusted EPS. Labcorp received FDA approval for a melanoma diagnostic test and announced several acquisitions and partnerships, including deals with BioReference Health, Myriad Genetics, and Millennium Health.

Labcorp (LH) and Waters Corporation (WAT) partner to expand access to the FDA-approved BD Onclarity HPV Assay for cervical cancer screening, starting late 2026. The test supports all ASCCP guidelines and offers extended genotyping. Labcorp will provide testing through its nationwide network, aiming to address screening gaps and improve access for patients.

Charles River Laboratories (NYSE:CRL) partnered with the FDA and Labcorp to develop tools for assessing drug abuse potential. The collaboration aims to standardize metrics for preclinical abuse potential evaluations, using behavioral economic models. Charles River has conducted over 100 such studies and contributed to 15 FDA-approved products.

OPKO Health (OPK) agreed to sell select BioReference Health assets to Labcorp for $722M+ in cash, with a potential $150M earnout. The deal, subject to regulatory approval, includes clinical and women's health testing services and over 80 patient service centers. According to OPKO, the price may adjust based on closing revenues.

Labcorp (NYSE: LH) announced a quarterly dividend of $0.72 per share, payable on December 11. The company is a global leader in laboratory services, supporting clients in around 100 countries. This dividend declaration is relevant for investors tracking income-generating opportunities.

MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp Transaction to benefit patients through expanded access and support Myriad’s strategic priorities SALT LAKE CITY and BURLINGTON, N.C., October 20,

Myriad Genetics (MYGN) will sell its Prenatal Health unit to Labcorp for $210M in cash, plus inventory value. The deal is subject to regulatory approval and expected to close by early 2027. Myriad aims to focus on cancer diagnostics, while Labcorp expands its testing services.

Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.